Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the <scp>RECOMB</scp> studyEsteban Ribera, Estebán Martínez, Rafael Rubio et al.|HIV Medicine|2013Cited by 12
Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratioEstebán Martínez, ML Álvarez, Esteban Ribera et al.|HIV Medicine|2014Cited by 4
48-week outcomes following switch from AZT/3TC to FTC/TDF (TVD) vs. continuing on AZT/3TC: 48-week interim analysis of the RECOMB trialEsteban Ribera, ML Álvarez, Bonaventura Clotet et al.|Journal of the International AIDS Society|2008Cited by 2
Subclinical atherosclerosis burden in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factorsPedro Eitz Ferrer, Vicente Estrada, Noemí Cabello et al.|BMC Infectious Diseases|2024Cited by 2